Pioneer of Tumor Immunotherapy Dr. Francesco Marincola Appointed as Chairman of Batu Biologics Clinical Advisory Board
25 März 2018 - 1:22AM
Business Wire
Former President of the Society for
Immunotherapy of Cancer to Assist Company in Advancement of its
Anti-Angiogenesis Immunotherapy Product ValloVax
Batu Biologics, committed to advancement of its clinical stage
cancer immunotherapeutic, ValloVax™, announced today the
appointment of Dr. Francesco Marincola as the Chairman of the
Company’s Clinical Advisory Board.
Dr. Marincola has pioneered research in tumor immunology by
developing strategies for studying tumor-host interactions in the
context of human genetic polymorphism and cancer heterogeneity.
During his tenure as a Senior Staff Scientist with the NCI Surgery
Branch, Dr. Marincola investigated the identification of the
algorithm responsible for tumor rejection by immune cells
particularly in the context of metastatic melanoma. Specifically,
the focus of his research is the optimization of strategies to
study clinical material during the conduct of clinical trials. Dr.
Marincola is author of over 500 peer reviewed papers and is
considered one of the world’s top experts in tumor
immunotherapy.
“It is my honor to welcome Dr. Marincola to Chair our Clinical
Advisory Board. Having previously worked and published with Dr.
Marincola, I am very excited about collaborating in advancing our
cancer immunotherapeutic that selectively kills tumor blood
vessels,” said Samuel Wagner, President and CEO of Batu
Biologics.
Batu Biologics has obtained FDA clearance to initiate clinical
trials of its ValloVax product which has been published to induce
immune responses to what is believed to be the “Achilles Heel” of
cancer: its blood supply.
“Despite the great progress that has occurred in the field of
immuno-oncology, many patients still do not respond to approaches
such as checkpoint inhibitors,” said Dr. Marincola. “I am
enthusiastic about leading the scientific direction of the Company
as it seeks to develop a totally new approach to cancer
immunotherapy.”
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180324005030/en/
Batu BiologicsDimitri Theofilopoulos, J.D., 213-359-3179Chief
Operations OfficerFax:
858-597-7090dimitri.theo@batubiologics.comwww.batubiologics.com(No
Solicitations)